Abstract

ObjectivesThere is a need for effective and safe treatment during pregnancy in women with chronic inflammatory diseases. This study evaluated placental transfer of certolizumab pegol (CZP), an Fc-free anti-tumour necrosis...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
OP0017 Lack of placental transfer of certolizumab pegol during pregnancy: results from crib, a prospective, postmarketing, multicenter, pharmacokinetic study
R-M Flipo ... A Moltό
Annals of the Rheumatic Diseases | VOL. 76
R-M Flipo, et. al.R-M Flipo ... A Moltό
01 Jun 2017
FRI0179 Minimal to no transfer of certolizumab pegol into breast milk: results from cradle, a prospective, postmarketing, multicenter, pharmacokinetic study
Meb Clowse ... Tw Hale
Annals of the Rheumatic Diseases | VOL. 76
Meb Clowse, et. al.Meb Clowse ... Tw Hale
01 Jun 2017
Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study
Astrid Van Tubergen ... Thomas W Hale
Annals of the Rheumatic Diseases | VOL. 76
Astrid Van Tubergen, et. al.Astrid Van Tubergen ... Thomas W Hale
16 Aug 2017
Evaluating Placental Transfer of Certolizumab Pegol and Polyethylene Glycol During Pregnancy: Results From CRIB, a Prospective, Post-Marketing, Multicenter, Pharmacokinetic Study
Frauke Förger ... Anna Moltó
American Journal of Gastroenterology | VOL. 112
Frauke Förger, et. al.Frauke Förger ... Anna Moltó
01 Oct 2017
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers